Boston Scientific (BSX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
18 Mar, 2026Voting matters and shareholder proposals
Election of ten directors is proposed, with board recommending a vote for each nominee.
Advisory vote on executive compensation is recommended for approval.
Ratification of Ernst & Young LLP as independent auditor for 2026 fiscal year is recommended.
Amendments to the Employee Stock Purchase Plan to increase reserved shares are proposed.
Amendments to the Certificate of Incorporation to remove supermajority voting, provide officer exculpation, and allow 25% shareholders to call special meetings are recommended.
Board recommends voting against a shareholder proposal to give shareholders the ability to call special meetings.
Board of directors and corporate governance
Ten director nominees are listed for election at the annual meeting.
Proposed amendments would enhance shareholder rights by lowering thresholds for calling special meetings.
Executive compensation and say-on-pay
Advisory vote on executive compensation for named executive officers is included, with board support.
Latest events from Boston Scientific
- 2025 performance exceeded targets, driving pay-for-performance and governance reforms.BSX
Proxy Filing18 Mar 2026 - Shareholders to vote on director elections, executive pay, auditor, and major governance changes.BSX
Proxy Filing6 Mar 2026 - Double-digit growth, innovation in EP/PFA, and portfolio expansion drive strong outlook.BSX
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Double-digit sales and EPS growth in 2025, with strong 2026 outlook and innovation momentum.BSX
Q4 20254 Feb 2026 - Q2 net sales up 14.5% to $4.12B, adjusted EPS $0.62, and guidance raised for 2024.BSX
Q2 20243 Feb 2026 - FARAPULSE and WATCHMAN fuel rapid growth, with global expansion and major clinical milestones ahead.BSX
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Q3 2024 net sales rose 19.4% and adjusted EPS grew 27%, both exceeding guidance.BSX
Q3 202419 Jan 2026 - Cardiology sales surged 23% YTD 2024, fueled by innovation and global expansion.BSX
Status Update17 Jan 2026 - $15B acquisition expands into high-growth vascular markets, accretive by year three.BSX
M&A announcement15 Jan 2026